Latest KFF Health News Stories
Social Media Is Fueling Enthusiasm for New Weight Loss Drugs. Are Regulators Watching?
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
KFF Health News' 'What the Health?': The Confusing Fate of the Abortion Pill
The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
Montana May Require Insurers to Cover Monitoring Devices for Diabetes
Montana is one of several states considering expanding coverage of continuous glucose monitors, but insurance companies and some providers argue that not all people with diabetes need them.
Journalists Delve Into Insulin Costs and Prior Authorization Policy
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Fresh Produce Is an Increasingly Popular Prescription for Chronically Ill Patients
Fresh produce prescription programs are getting a boost in Montana as a way of helping people with chronic conditions such as diabetes and high blood pressure. The approach may be a model for other rural states to promote healthy eating in food deserts.
California Picks Generic Drug Company Civica to Produce Low-Cost Insulin
Gov. Gavin Newsom, who blasted pharmaceutical companies for gouging Californians, is moving ahead with state-branded insulin. He’s also eyeing other generic drugs.
California eligió a la compañía de genéricos Civica para producir insulina de bajo costo
Civica está desarrollando tres tipos de insulina genérica, conocida como biosimilar, que estarán disponibles tanto en viales como en plumas inyectables, a un costo de entre $30 y $55.
La insulina representa lo perverso del sistema sanitario estadounidense, ya que los precios de venta de este medicamento centenario, del que dependen 8,4 millones de estadounidenses para sobrevivir, se quintuplicaron en dos décadas.
Why Does Insulin Cost So Much? Big Pharma Isn’t the Only Player Driving Prices
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it’s the arbitrators that jack up prices for those who can least afford them.
Journalists Discuss Insulin Prices, Gun Violence, Distracted Driving, and More
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Decisión de Eli Lilly de bajar el precio de su insulina logrará cambios históricos en los costos
Expertos en precios de medicamentos celebraron la noticia de Eli Lilly y otros esfuerzos. Y estas otras iniciativas para llevar al mercado insulina de menor costo, a su vez, presionarían a Eli Lilly para que mantuviera sus precios bajos.
Eli Lilly Slashed Insulin Prices. This Starts a Race to the Bottom.
Eli Lilly’s news that it plans to cut insulin costs for patients will help, not hinder, the recent efforts in California and by entrepreneurs such as Mark Cuban to offer lower-cost alternatives, drug pricing experts said.
Armed With Hashtags, These Activists Made Insulin Prices a Presidential Talking Point
Twitter has been a hotbed for the burgeoning insulin access movement and activism surrounding other medical conditions. For people with diabetes, the platform has helped propel concern about insulin prices into policy. Can it continue to win with hashtags?
California Attorney General Sues Drugmakers Over Inflated Insulin Prices
California Attorney General Rob Bonta is taking three major drugmakers and three distributors to court, alleging the companies illegally raised prices at the expense of diabetes patients.
Fiscal general de California demanda a farmacéuticas por “inflar” los precios de la insulina
En la demanda, Rob Bonta argumentó que los precios se han disparado y que algunos pacientes se han visto obligados a racionar sus medicamentos o renunciar por completo a comprar insulina.
A Retiree Returns to Work After a Calamitous Year of Health Emergencies
In 2020, diabetes and covid-19 landed David Zipprich in the hospital three times. Even with insurance, he was inundated with bills, debt notices, and calls from collectors.
Watch: The Politics of Health Care in California
KHN senior correspondent Angela Hart discussed the most pressing health care issues in California with the nonpartisan group Democracy Winters in mid-November, touching on a variety of issues, from the state’s effort to transform its Medicaid program to its plan to produce generic insulin.
Medicare Plan Finder Likely Won’t Note New $35 Cap on Out-of-Pocket Insulin Costs
In August, Congress approved a $35 cap on what seniors will pay for insulin, but that change came too late to add to the online tool that helps Medicare beneficiaries compare dozens of drug and medical plans. Federal officials say beneficiaries who use insulin will have the opportunity to switch plans after open enrollment ends Dec. 7.
You may have seen the ads that promise weight loss and better health — phone apps, rings, and other devices — by giving you data on how your body reacts to food, exercise, and sleep. Is this information enough to help consumers achieve their goals?
‘An Arm and a Leg’: Checking Up on California’s DIY Insulin Project
California put up $100 million to produce its own insulin. How did this plan come to be, and what might stand in the state’s way?
